$KALV
KalVista Pharmaceuticals, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015007264 Filed on August 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $10.00K $10.00K
YoY Change 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.170M $690.0K
YoY Change 69.57%
% of Gross Profit
Research & Development $4.500M $1.750M
YoY Change 157.14%
% of Gross Profit
Depreciation & Amortization $40.00K $10.00K
YoY Change 300.0% 0.0%
% of Gross Profit
Operating Expenses $5.674M $2.441M
YoY Change 132.45%
Operating Profit
YoY Change
Interest Expense -$170.0K -$80.00K
YoY Change 112.5%
% of Operating Profit
Other Income/Expense, Net -$3.345M -$199.0K
YoY Change 1580.9%
Pretax Income -$9.010M -$2.640M
YoY Change 241.29%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.012M -$2.635M
YoY Change 242.01%
Net Earnings / Revenue -90120.0% -26350.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$5.178M -$2.422M
COMMON SHARES
Basic Shares Outstanding 26.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.40M $7.200M
YoY Change 808.33%
Cash & Equivalents $2.526M $481.0K
Short-Term Investments
Other Short-Term Assets $1.600M $200.0K
YoY Change 700.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $67.00M $7.400M
YoY Change 805.41%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $100.0K
YoY Change 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $100.0K
YoY Change 100.0%
Total Long-Term Assets $600.0K $200.0K
YoY Change 200.0%
TOTAL ASSETS
Total Short-Term Assets $67.00M $7.400M
Total Long-Term Assets $600.0K $200.0K
Total Assets $67.60M $7.600M
YoY Change 789.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $700.0K
YoY Change 185.71%
Accrued Expenses $1.700M $700.0K
YoY Change 142.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $500.0K $4.100M
YoY Change -87.8%
Total Short-Term Liabilities $4.200M $5.600M
YoY Change -25.0%
LONG-TERM LIABILITIES
Long-Term Debt $4.000M $0.00
YoY Change
Other Long-Term Liabilities $100.0K $500.0K
YoY Change -80.0%
Total Long-Term Liabilities $4.100M $500.0K
YoY Change 720.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.200M $5.600M
Total Long-Term Liabilities $4.100M $500.0K
Total Liabilities $8.300M $6.100M
YoY Change 36.07%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$23.56M -$16.21M
YoY Change
Total Liabilities & Shareholders Equity $67.60M $7.600M
YoY Change 789.47%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$9.012M -$2.635M
YoY Change 242.01%
Depreciation, Depletion And Amortization $40.00K $10.00K
YoY Change 300.0% 0.0%
Cash From Operating Activities -$6.440M -$1.940M
YoY Change 231.96% -23.02%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K -$80.00K
YoY Change 0.0% 700.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$80.00K -$80.00K
YoY Change 0.0% 700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 68.72M -90.00K
YoY Change -76455.56% -101.41%
NET CHANGE
Cash From Operating Activities -6.440M -1.940M
Cash From Investing Activities -80.00K -80.00K
Cash From Financing Activities 68.72M -90.00K
Net Change In Cash 62.20M -2.110M
YoY Change -3047.87% -154.52%
FREE CASH FLOW
Cash From Operating Activities -$6.440M -$1.940M
Capital Expenditures -$80.00K -$80.00K
Free Cash Flow -$6.360M -$1.860M
YoY Change 241.94% -25.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
-4650000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3345000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-199000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-358000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-9012000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2635000
us-gaap Net Income Loss
NetIncomeLoss
-14196000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3628000
CY2015Q2 cbyl Interest Income
InterestIncome
2000
CY2014Q2 cbyl Interest Income
InterestIncome
1000
cbyl Interest Income
InterestIncome
2000
cbyl Interest Income
InterestIncome
1000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3177000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-196000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.62
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24303819
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
618451
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12568098
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
539308
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
65000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
155000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
109000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-520000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
191000
us-gaap Paid In Kind Interest
PaidInKindInterest
157000
us-gaap Paid In Kind Interest
PaidInKindInterest
93000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
758000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
924000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
54000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
793000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
275000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
59000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
335000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10490000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3692000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
259000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
76000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-259000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-76000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
149000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
205000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
68084000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-10000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
282000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
72233000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1163000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
61484000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2605000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9781000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7176000
us-gaap Interest Paid
InterestPaid
45000
us-gaap Interest Paid
InterestPaid
59000
cbyl Noncash Issuance Of Preferred Stock Warrants
NoncashIssuanceOfPreferredStockWarrants
19000
cbyl Conversion Of Warrant Amount Converted
ConversionOfWarrantAmountConverted
347000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
39556000
cbyl Non Cash Increase Accrual Of Deferred Public Offering Costs
NonCashIncreaseAccrualOfDeferredPublicOfferingCosts
175000
cbyl Non Cash Increase Accrual Of Deferred Public Offering Costs
NonCashIncreaseAccrualOfDeferredPublicOfferingCosts
15000
cbyl Non Cash Increase Of Derivative Liability Relates To Convertible Promissory Notes At Issuance
NonCashIncreaseOfDerivativeLiabilityRelatesToConvertiblePromissoryNotesAtIssuance
1196000
cbyl Noncash Or Part Noncash Increase Of Beneficial Conversion Feature For Convertible Promissory Notes
NoncashOrPartNoncashIncreaseOfBeneficialConversionFeatureForConvertiblePromissoryNotes
519000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of the interim condensed financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to common stock, stock-based compensation expense, warrant liabilities, accruals, derivative liability, deferred tax valuation allowance and revenue recognition. Management bases its estimates on historical experience or on various other assumptions, including information received from its service providers, which it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company invests its excess cash in money market accounts. The Company&#8217;s cash and cash equivalents are held by a single financial institution and all cash is held in the United States. Such deposits may, at times, exceed federally insured limits. The Company has not recognized any losses during the periods presented and management does not believe that the Company is exposed to significant credit risk from its cash and cash equivalents.</p></div>
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Embedded Derivatives Related to Convertible Promissory Notes</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e. host) are accounted for and valued as a separate financial instrument. The Company evaluated the terms and features of the convertible promissory notes issued in September 2014 and February 2015 and identified embedded derivatives requiring bifurcation and accounting at fair value because the economic and contractual characteristics of the embedded derivatives met the criteria for bifurcation and separate accounting due to the conversion features (see Note 7 for a description of the conversion features).</p></div>
us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
16000
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2004-03-26
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In March 2015, the Company’s board of directors and stockholders approved a 4-for-1 reverse stock split of the Company’s common and preferred stock. The Company filed an amendment to its certificate of incorporation effecting the reverse stock split on March 13, 2015. All issued and outstanding common stock, convertible preferred stock, warrants for preferred stock, options for common stock and per share amounts contained in the condensed financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2015Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
105000000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
65356000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3875000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1958000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
934000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
675000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
560000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
495000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
586000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
723000
CY2015Q2 cbyl Accrued Legal Expenses
AccruedLegalExpenses
73000
CY2014Q4 cbyl Accrued Legal Expenses
AccruedLegalExpenses
159000
CY2015Q2 cbyl Accrued Research And Clinical Trial Expenses
AccruedResearchAndClinicalTrialExpenses
943000
CY2014Q4 cbyl Accrued Research And Clinical Trial Expenses
AccruedResearchAndClinicalTrialExpenses
380000
CY2015Q2 cbyl Accrued Professional Fees Excluding Legal Fees Current
AccruedProfessionalFeesExcludingLegalFeesCurrent
64000
CY2014Q4 cbyl Accrued Professional Fees Excluding Legal Fees Current
AccruedProfessionalFeesExcludingLegalFeesCurrent
343000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
124729
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
218000
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
213000
CY2015Q2 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
48000
CY2014Q2 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
47000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
97000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
94000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
220000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
73000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
293000
CY2015Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
110000
CY2014Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
107000
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50000
CY2015Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2015Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
500000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001564590-15-007264-index-headers.html Edgar Link pending
0001564590-15-007264-index.html Edgar Link pending
0001564590-15-007264.txt Edgar Link pending
0001564590-15-007264-xbrl.zip Edgar Link pending
cbyl-10q_20150630.htm Edgar Link pending
cbyl-20150630.xml Edgar Link completed
cbyl-20150630.xsd Edgar Link pending
cbyl-20150630_cal.xml Edgar Link unprocessable
cbyl-20150630_def.xml Edgar Link unprocessable
cbyl-20150630_lab.xml Edgar Link unprocessable
cbyl-20150630_pre.xml Edgar Link unprocessable
cbyl-ex311_201506308.htm Edgar Link pending
cbyl-ex312_201506307.htm Edgar Link pending
cbyl-ex321_201506306.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending